Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
142.74
-1.75 (-1.21%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novo Nordisk A/S ADR
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
49
50
Next >
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising
December 07, 2023
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale.
Via
Investor's Business Daily
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
December 06, 2023
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer
Via
Benzinga
Obesity Drugs: Greater Weight Loss Linked to Prolonged Use of Novo Nordisk's Wegovy
December 06, 2023
A recent analysis of medical records and insurance claims data revealed that 40% of patients who received prescriptions for Novo Nordisk A/S's (NYSE: NVO) obesity treatment drug Wegovy in 2021 or 2022...
Via
Benzinga
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
December 04, 2023
Via
Benzinga
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
December 04, 2023
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic
Via
Benzinga
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
December 02, 2023
This company famously helps manage a prevalent chronic illness.
Via
The Motley Fool
Will NOVO-NORDISK A/S-SPONS ADR breakout?
November 30, 2023
The technical analysis for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is highly positive, with a rating of 10 out of 10, suggesting a potential breakout.
Via
Chartmill
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
December 04, 2023
Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news.
Via
Investor's Business Daily
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
December 04, 2023
Roche Holding AG (OTC: RHHBY) has agreed to
Via
Benzinga
1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague
December 04, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's a historically cheap outperformer, as well as an industry leader that could...
Via
The Motley Fool
3 No-Brainer Growth Stocks to Buy in December
December 03, 2023
No analysis paralysis is required with these great stocks.
Via
The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
December 02, 2023
With shares already reflecting a post-COVID dearth of revenue streams, Pfizer's growth outlook recently took another hit as it halted development of its experimental weight-loss pill after a high rate...
Via
Talk Markets
An Important History Lesson for Gene-Editing Investors
December 02, 2023
Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.
Via
The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
December 02, 2023
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.
Via
The Motley Fool
Advocacy for Wegovy: Denmark Signals Cost-Sharing Talks While Novo Spent Millions On Medical Community For Drug Promotion
December 01, 2023
Denmark's Health Minister, Sophie Lohde, has signaled the government's willingness to expand coverage for Novo Nordisk A/S's (NYSE: NVO) weight-loss drug Wegovy if the company shares some of the...
Via
Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
December 01, 2023
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...
Via
Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
December 01, 2023
Cantor Fitzgerald has initiated coverage on Europe's most valuable company, Novo Nordisk A/S (NYSE: NVO).
Via
Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
December 01, 2023
Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell.
Via
Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
December 01, 2023
Software earnings were strong, while the Fed is shifting toward rate cuts.
Via
Investor's Business Daily
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
December 01, 2023
Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug.
Via
Talk Markets
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?
December 01, 2023
Novo Nordisk stock has been a red-hot buy this year -- can it continue that trend through this decade?
Via
The Motley Fool
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
November 30, 2023
Novo Nordisk A/S (NYSE: NVO) has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
November 30, 2023
Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy.
Via
The Motley Fool
Counterfeit Ozempic Raises Alarms - Lebanon Reports Hypoglycemia Cases
November 29, 2023
Lebanese health officials have reported eleven cases of severe hypoglycemia linked to suspected fake versions of Novo Nordisk A/S's (NYSE: NVO)
Via
Benzinga
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
November 29, 2023
Real-world data showed some real-world advantages for Ozempic's top rival.
Via
The Motley Fool
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
November 28, 2023
The study examined health care records for more than 41,000 people.
Via
Investor's Business Daily
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
November 28, 2023
A recent extensive analysis by Truveta Research has
Via
Benzinga
Only Have $100? 3 No-Brainer Stocks to Buy Right Now
November 28, 2023
The stock market is such a well-oiled, wealth-generating machine that investors can start with just $100 to buy these no-brainer stocks.
Via
InvestorPlace
Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
November 27, 2023
Novo Nordisk A/S (NYSE: NVO) is reportedly discussing with healthcare systems to introduce innovative pricing arrangements for its popular weight
Via
Benzinga
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
November 26, 2023
An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares.
Via
The Motley Fool
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
49
50
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.